Semafore Pharmaceuticals is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics targeting the phosphoinositide-3-kinase (PI3K) pathway for the treatment of cancer and other serious diseases.
Semafore Pharmaceuticals has successfully discovered and developed a portfolio of proprietary, unpartnered drug candidates. The company’s lead clinical product candidate, SF1126, is unique among clinical stage, dual PI3K-mTOR inhibitors as it is a prodrug designed to selectively inhibit PI3K by targeting integrins expressed on the surface of new tumor vasculature and within the tumor compartment. The company’s preclinical pipeline includes SF2626, which has demonstrated the ability to inhibit both PI3K and mitogen-activated protein kinase (MEK), the key component of the RAS/RAF/MEK/ERK pathway.